<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01480297</url>
  </required_header>
  <id_info>
    <org_study_id>SALP</org_study_id>
    <nct_id>NCT01480297</nct_id>
  </id_info>
  <brief_title>Pilot Study to Determine Effects of Salsalate in Type 1 Diabetes and Painful Peripheral Neuropathy</brief_title>
  <acronym>SALP</acronym>
  <official_title>A Pilot Study to Determine the Effects of 12 Weeks of Treatment With Salsalate on Measures of Peripheral Neuropathy in Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 12 week study will examine the effects of daily Salsalate treatment on markers of
      neuropathic pain and intra-epidermal nerve fiber density. the study is being done in people
      with type 1 diabetes with signs and symptoms of peripheral neuropathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project will be used to establish preliminary data for a planned NIH-sponsored
      multicenter study of the effects of salsalate on diabetic neuropathy (DN) in people with type
      1 diabetes. Diabetic peripheral neuropathy (DN) ultimately affects one-half of the patients
      with type 1 diabetes (T1DM) and is a major cause of disability, high mortality, and poor
      quality of life. Although intensive glucose control has proven efficacy in delaying or
      preventing DN in T1DM and type 2 diabetes (T2DM), most people with diabetes do not reach and
      maintain glycemic levels needed to achieve these benefits. In addition, many patients with
      diabetes still develop diabetic complications, including DN, despite good glucose control.
      For DN, no disease modifying treatment other than glycemic control is available. Therefore,
      it is essential to identify new drug targets and to treat DN as early as possible in its
      course.

      The investigators planned, multi-center study will be the first to determine the effect of an
      anti-inflammatory agent, salsalate, on DN development and progression, and on DN pain in type
      1 diabetes. This proof-of-concept pilot study will measure the effects of short term (12
      week) treatment with Salsalate on novel and on established measures of peripheral neuropathy.
      Ultimately, this may permit measurement of treatment effects over a shorter period of time
      than by using established measures such as nerve conduction studies. Salsalate, a prodrug
      form of salicylate, is used to treat osteoarthritis and other rheumatologic conditions. It is
      highly effective in modulating the IKKβ/NF-κB pathway, with a large margin of safety, and has
      a glucose lowering effect in patients with type 2 diabetes. The IKKβ/NF-κB pathway is unique
      in that it is implicated in both the pathogenesis of nerve fiber loss as well as pain in DN.
      The proposed study design employs a quantifiable early measure of DN, IENFD of the thigh,
      allowing for accurate assessment of actual nerve fiber density over time.

      In the pilot study, biomarkers of pain found in IENF's as well as IENFD will be measured pre
      and post 3 months of treatment with Salsalate, 3 grams daily.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intra-epidermal Nerve Fiber Density (IENFD) Fibers Per mm</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Intra-epidermal Nerve Fiber Density (IENFD) was measured at two anatomic locations (thigh and ankle) at baseline and after 12 weeks of treatment with Salsalate. IENFD is expressed as fibers per mm. Means and standard deviations are shown.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Peripheral Neuropathy</condition>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Salsalate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will take Salsalate, 3 grams daily (as 3 divided doses of 1 gram with breakfast, lunch and dinner).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salsalate</intervention_name>
    <description>Salsalate 3 grams daily (1 gram TID with meals)</description>
    <arm_group_label>Salsalate</arm_group_label>
    <other_name>Salsalate (Amneal Pharmaceuticals)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetes (T1D)

          -  Peripheral neuropathy with symptoms of pain, or with other uncomfortable symptoms
             (e.g., burning, prickling).

          -  18 to 70 years old

          -  Stable insulin treatment program for at least the past 3 months.

          -  Abnormal nerve conduction studies (based on study screening examination)

          -  Willing and able to take an oral (by mouth) medication 3 times per day for 3 months.

          -  WOMEN using an appropriate method of contraception during the course of the study
             (hormonal, IUD, or diaphragm.

          -  Willing and able to provide written informed consent for study participation.

        Exclusion Criteria:

          -  Neuropathy from a cause other than diabetes.

          -  Allergy to salsalate or similar medications (aspirin, non-steroidal anti-inflammatory
             medicines like ibuprofen and naproxen).

          -  Currently on blood thinning agents such as Coumadin, Heparin, Plavix, Pradaxa,
             high-dose aspirin (more than 325 mg daily).

          -  Any severe low blood sugar episodes in the past 6 months (needed assistance to treat).

          -  Diabetic ketoacidosis in the past 6 months.

          -  Severe neuropathy, or have had an ulcer or amputation on either foot or either leg.

          -  Creatinine level (a measure of kidney function is greater than 1.4 mg/dl (for women)
             or greater than 1.5 mg/dl (for men) or your estimated GFR is under 60.

          -  Albumin in your urine or other signs of reduced kidney function.

          -  Liver enzymes (including ALT, AST and Bilirubin) levels are more than 2 and ½ times
             the upper limit of normal.

          -  Blood platelets are less than 100,000 at the time of screening.

          -  Organ transplant (lung, kidney, heart, pancreas, liver).

          -  Chronic immunosuppressive therapy, for example, daily prednisone or other steroids,
             methotrexate, Imuran, CellCept. This includes daily, or recurrent use of oral steroids
             used to treat asthma.

          -  Regular NSAID medications (e.g., Naproxen, Ibuprofen) use. If used occasionally, you
             will be asked to not use them during the study.

          -  History of drug or alcohol abuse, or if you take more than 10 alcoholic drinks per
             week.

          -  History of stomach ulcers or bleeding from your bowel.

          -  Heart attack, heart bypass surgery, heart failure or a stroke EVER.

          -  Current treatment for any cancer (other than basal cell or squamous cell skin cancer).

          -  Treatment with lithium.

          -  Ever had Reyes' syndrome.

          -  Pregnant, nursing, or planning to become pregnant during the time of the study.

          -  Allergic to lidocaine or epinephrine (used for numbing skin prior to biopsies).

          -  Keloid scarring in the past.

          -  Receiving other experimental treatments.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodica Pop-Busui, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan, Department of Internal Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2011</study_first_submitted>
  <study_first_submitted_qc>November 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2011</study_first_posted>
  <results_first_submitted>December 2, 2014</results_first_submitted>
  <results_first_submitted_qc>April 23, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 24, 2015</results_first_posted>
  <last_update_submitted>April 23, 2015</last_update_submitted>
  <last_update_submitted_qc>April 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Rodica Pop-Busui</investigator_full_name>
    <investigator_title>Associate Professor of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Neuropathy</keyword>
  <keyword>Diabetes type 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salicylsalicylic acid</mesh_term>
    <mesh_term>Sodium Salicylate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment was completed in 3 months time.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Salsalate</title>
          <description>All subjects will take Salsalate, 3 grams daily (as 3 divided doses of 1 gram with breakfast, lunch and dinner).
Salsalate: Salsalate 3 grams daily (1 gram TID with meals)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>adults with type 1 diabetes and painful peripheral neuropathy</population>
      <group_list>
        <group group_id="B1">
          <title>Salsalate</title>
          <description>All subjects will take Salsalate, 3 grams daily (as 3 divided doses of 1 gram with breakfast, lunch and dinner).
Salsalate: Salsalate 3 grams daily (1 gram TID with meals)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.0" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Intra-epidermal Nerve Fiber Density (IENFD) Fibers Per mm</title>
        <description>Intra-epidermal Nerve Fiber Density (IENFD) was measured at two anatomic locations (thigh and ankle) at baseline and after 12 weeks of treatment with Salsalate. IENFD is expressed as fibers per mm. Means and standard deviations are shown.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Type 1 diabetes with painful neuropathy</population>
        <group_list>
          <group group_id="O1">
            <title>Salsalate</title>
            <description>All subjects will take Salsalate, 3 grams daily (as 3 divided doses of 1 gram with breakfast, lunch and dinner).
Salsalate: Salsalate 3 grams daily (1 gram TID with meals)</description>
          </group>
        </group_list>
        <measure>
          <title>Intra-epidermal Nerve Fiber Density (IENFD) Fibers Per mm</title>
          <description>Intra-epidermal Nerve Fiber Density (IENFD) was measured at two anatomic locations (thigh and ankle) at baseline and after 12 weeks of treatment with Salsalate. IENFD is expressed as fibers per mm. Means and standard deviations are shown.</description>
          <population>Type 1 diabetes with painful neuropathy</population>
          <units>fibers per mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Thigh IENFD(fibers per mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Ankle IENFD(fibers per mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Week Thigh IENFD(fibers per mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Week Ankle IENFD(fibers per mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Salsalate</title>
          <description>All subjects will take Salsalate, 3 grams daily (as 3 divided doses of 1 gram with breakfast, lunch and dinner).
Salsalate: Salsalate 3 grams daily (1 gram TID with meals)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Severe Hypoglycemia</sub_title>
                <description>Severe hypoglycemia requiring emergency room treatment.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <description>3 of 8 subjects reported tinnitus. Tinnitus is a known side effect of Salsalate. In all cases, the Tinnitus resolved with decrease in dose, or with cessation of Salsalate treatment.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flashes</sub_title>
                <description>Patient (postmenopausal woman) reported an increase in hot flashes.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract Removal</sub_title>
                <description>Scheduled removal of cataracts</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Symptoms</sub_title>
                <description>Cold/Sinusitis</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Biopsy of Suspicious Lesion</sub_title>
                <description>Patient with suspicious lesion of face - biopsy was benign.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Increased Bleeding from Biopsy Site</sub_title>
                <description>Patient reported increased bleeding from a single biopsy site. Resolved with application of pressure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rodica Pop-Busui, MD, PhD</name_or_title>
      <organization>The University of Michigan</organization>
      <phone>734-763-3056</phone>
      <email>rpbusui@umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

